Intarcia’s Implantable GLP-1 Gets Unanimous No Vote But Lots Of New Trial Design Advice

 
• By Sarah Karlin-Smith
  
Intarcia’s last-ditch attempt to change FDA’s mind on its diabetes implant looks unlikely after negative advisory panel vote • Source: Shutterstock

More from Regulation

More from Policy & Regulation